1
|
Carlos ECDS, Cristovão GA, Silva AA, Ribeiro BCDS, Romana‐Souza B. Imiquimod‐induced
ex vivo
model of psoriatic human skin via
interleukin‐17A
signaling of T cells and Langerhans cells. Exp Dermatol 2022; 31:1791-1799. [DOI: 10.1111/exd.14659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 07/22/2022] [Accepted: 08/09/2022] [Indexed: 11/27/2022]
Affiliation(s)
| | | | - Alcimar Alves Silva
- Department of Histology and Embryology Rio de Janeiro State University Rio de Janeiro Brazil
| | | | - Bruna Romana‐Souza
- Department of Histology and Embryology Rio de Janeiro State University Rio de Janeiro Brazil
| |
Collapse
|
2
|
Scholz T, Weigert A, Brüne B, Sadik CD, Böhm B, Burkhardt H. GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency. PLoS One 2017; 12:e0182646. [PMID: 28777803 PMCID: PMC5544216 DOI: 10.1371/journal.pone.0182646] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Accepted: 07/21/2017] [Indexed: 01/21/2023] Open
Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic, Th17-derived cytokine thought to critically contribute to the pathogenesis of diverse autoimmune diseases, including rheumatoid arthritis and psoriasis. Treatment with monoclonal antibodies that block GM-CSF activity is associated with favorable therapeutic effects in patients with rheumatoid arthritis. We evaluated the role of GM-CSF as a potential target for therapeutic interference in psoriasis using a combined pharmacologic and genetic approach and the mouse model of imiquimod-induced psoriasiform dermatitis (IMQPD). Neutralization of murine GM-CSF by an anti-GM-CSF antibody ameliorated IMQPD. In contrast, genetic deficiency in GM-CSF did not alter the course of IMQPD, suggesting the existence of mechanisms compensating for chronic, but not acute, absence of GM-CSF. Further investigation uncovered an alternative pathogenic pathway for IMQPD in the absence of GM-CSF characterized by an expanded plasmacytoid dendritic cell population and release of IFNα and IL-22. This pathway was not activated in wild-type mice during short-term anti-GM-CSF treatment. Our investigations support the potential value of GM-CSF as a therapeutic target in psoriatic disease. The discovery of an alternative pathogenic pathway for psoriasiform dermatitis in the permanent absence of GM-CSF, however, suggests the need for monitoring during therapeutic use of long-term GM-CSF blockade.
Collapse
Affiliation(s)
- Tatjana Scholz
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Goethe University, Frankfurt am Main, Germany
| | - Andreas Weigert
- Institute of Biochemistry I-Pathobiochemistry, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany
| | - Bernhard Brüne
- Institute of Biochemistry I-Pathobiochemistry, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany
| | - Christian D. Sadik
- Department of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany
| | - Beate Böhm
- Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Harald Burkhardt
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Goethe University, Frankfurt am Main, Germany
- Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
- * E-mail:
| |
Collapse
|
3
|
Vinter H, Kragballe K, Steiniche T, Gaestel M, Iversen L, Johansen C. Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice. Br J Dermatol 2016; 174:1011-21. [DOI: 10.1111/bjd.14320] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/23/2015] [Indexed: 12/24/2022]
Affiliation(s)
- H. Vinter
- Department of Dermatology; Aarhus University Hospital; P. P. Oerumsgade 11 Building 15B DK-8000 Aarhus C Denmark
| | - K. Kragballe
- Department of Dermatology; Aarhus University Hospital; P. P. Oerumsgade 11 Building 15B DK-8000 Aarhus C Denmark
| | - T. Steiniche
- Department of Pathology; Aarhus University Hospital; Tage Hansens Gade 2; DK-8000 Aarhus C Denmark
| | - M. Gaestel
- Institute of Biochemistry; Hannover Medical University; 30625 Hannover Germany
| | - L. Iversen
- Department of Dermatology; Aarhus University Hospital; P. P. Oerumsgade 11 Building 15B DK-8000 Aarhus C Denmark
| | - C. Johansen
- Department of Dermatology; Aarhus University Hospital; P. P. Oerumsgade 11 Building 15B DK-8000 Aarhus C Denmark
| |
Collapse
|
4
|
Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, Becher B. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest 2012; 122:2252-6. [PMID: 22546855 PMCID: PMC3366412 DOI: 10.1172/jci61862] [Citation(s) in RCA: 413] [Impact Index Per Article: 34.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2011] [Accepted: 03/14/2012] [Indexed: 12/14/2022] Open
Abstract
Psoriasis is a common, relapsing inflammatory skin disease characterized by erythematous scaly plaques. Histological manifestations of psoriasis include keratinocyte dysregulation and hyperproliferation, elongated rete ridges, and inflammatory infiltrates consisting of T cells, macrophages, dendritic cells, and neutrophils. Despite the availability of new effective drugs to treat psoriasis, the underlying mechanisms of pathogenesis are still poorly understood. Recent studies have shown that Aldara cream, used to treat benign skin abnormalities, triggers psoriasis-like disease in humans and mice and have implicated Th17 cells in disease initiation. Using this as a model, we found a predominant role for the Th17 signature cytokines IL-17A, IL-17F, and IL-22 in psoriasiform plaque formation in mice. Using gene-targeted mice, we observed that loss of Il17a, Il17f, or Il22 strongly reduced disease the severity of psoriasis. However, we found that Th17 cells were not the primary source of these pathogenic cytokines. Rather, IL-17A, IL-17F, and IL-22 were produced by a skin-invading population of γδ T cells and RORγt(+) innate lymphocytes. Furthermore, our findings establish that RORγt(+) innate lymphocytes and γδ T cells are necessary and sufficient for psoriatic plaque formation in an experimental disease model that closely resembles human psoriatic plaque formation.
Collapse
MESH Headings
- Adjuvants, Immunologic/pharmacology
- Administration, Topical
- Aminoquinolines/pharmacology
- Animals
- Dendritic Cells/immunology
- Dendritic Cells/pathology
- Disease Models, Animal
- Humans
- Imiquimod
- Interleukin-17/genetics
- Interleukin-17/immunology
- Interleukins/genetics
- Interleukins/immunology
- Macrophages/immunology
- Macrophages/pathology
- Mice
- Mice, Knockout
- Neutrophils/immunology
- Neutrophils/pathology
- Nuclear Receptor Subfamily 1, Group F, Member 3/genetics
- Nuclear Receptor Subfamily 1, Group F, Member 3/immunology
- Psoriasis/drug therapy
- Psoriasis/genetics
- Psoriasis/immunology
- Psoriasis/pathology
- Receptors, Antigen, T-Cell, gamma-delta/genetics
- Receptors, Antigen, T-Cell, gamma-delta/immunology
- Skin/immunology
- Skin/pathology
- T-Lymphocytes/immunology
- T-Lymphocytes/pathology
- Interleukin-22
Collapse
Affiliation(s)
- Stanislav Pantelyushin
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Department of Neuropathology, Charité–Universitätsmedizin Berlin, Berlin, Germany.
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
| | - Stefan Haak
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Department of Neuropathology, Charité–Universitätsmedizin Berlin, Berlin, Germany.
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
| | - Barbara Ingold
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Department of Neuropathology, Charité–Universitätsmedizin Berlin, Berlin, Germany.
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
| | - Paulina Kulig
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Department of Neuropathology, Charité–Universitätsmedizin Berlin, Berlin, Germany.
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
| | - Frank L. Heppner
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Department of Neuropathology, Charité–Universitätsmedizin Berlin, Berlin, Germany.
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
| | - Alexander A. Navarini
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Department of Neuropathology, Charité–Universitätsmedizin Berlin, Berlin, Germany.
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
| | - Burkhard Becher
- Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Department of Neuropathology, Charité–Universitätsmedizin Berlin, Berlin, Germany.
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
| |
Collapse
|
5
|
Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, Xing X, Nair RP, Voorhees JJ, Elder JT, Wang XJ, Sano S, Prens EP, DiGiovanni J, Pittelkow MR, Ward NL, Gudjonsson JE. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One 2011; 6:e18266. [PMID: 21483750 PMCID: PMC3070727 DOI: 10.1371/journal.pone.0018266] [Citation(s) in RCA: 147] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2011] [Accepted: 02/23/2011] [Indexed: 12/05/2022] Open
Abstract
Development of a suitable mouse model would facilitate the investigation of pathomechanisms underlying human psoriasis and would also assist in development of therapeutic treatments. However, while many psoriasis mouse models have been proposed, no single model recapitulates all features of the human disease, and standardized validation criteria for psoriasis mouse models have not been widely applied. In this study, whole-genome transcriptional profiling is used to compare gene expression patterns manifested by human psoriatic skin lesions with those that occur in five psoriasis mouse models (K5-Tie2, imiquimod, K14-AREG, K5-Stat3C and K5-TGFbeta1). While the cutaneous gene expression profiles associated with each mouse phenotype exhibited statistically significant similarity to the expression profile of psoriasis in humans, each model displayed distinctive sets of similarities and differences in comparison to human psoriasis. For all five models, correspondence to the human disease was strong with respect to genes involved in epidermal development and keratinization. Immune and inflammation-associated gene expression, in contrast, was more variable between models as compared to the human disease. These findings support the value of all five models as research tools, each with identifiable areas of convergence to and divergence from the human disease. Additionally, the approach used in this paper provides an objective and quantitative method for evaluation of proposed mouse models of psoriasis, which can be strategically applied in future studies to score strengths of mouse phenotypes relative to specific aspects of human psoriasis.
Collapse
Affiliation(s)
- William R. Swindell
- Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America
- * E-mail: (WRS); (JEG)
| | - Andrew Johnston
- Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America
| | - Steve Carbajal
- Division of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas, United States of America
| | - Gangwen Han
- Departments of Pathology, Otolaryngology and Dermatology, University of Colorado, Denver, Colorado, United States of America
| | - Christian Wohn
- Departments of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Jun Lu
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Xianying Xing
- Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America
| | - Rajan P. Nair
- Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America
| | - John J. Voorhees
- Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America
| | - James T. Elder
- Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America
- Ann Arbor Veterans Affairs Hospital, Ann Arbor, Michigan, United States of America
| | - Xiao-Jing Wang
- Departments of Pathology, Otolaryngology and Dermatology, University of Colorado, Denver, Colorado, United States of America
| | - Shigetoshi Sano
- Department of Dermatology, Kochi Medical School, Kochi University, Okocho, Nankoku, Japan
| | - Errol P. Prens
- Departments of Dermatology and Rheumatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - John DiGiovanni
- Department of Nutritional Sciences, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, Texas, United States of America
- Division of Pharmacology & Toxicology, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, Texas, United States of America
| | - Mark R. Pittelkow
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Nicole L. Ward
- Department of Dermatology and the Murdough Family Center for Psoriasis, Case Western Reserve University and University Hospitals, Case Medical Center, Cleveland, Ohio, United States of America
| | - Johann E. Gudjonsson
- Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America
- * E-mail: (WRS); (JEG)
| |
Collapse
|
6
|
Fang YP, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm 2009; 73:391-8. [PMID: 19660544 DOI: 10.1016/j.ejpb.2009.07.011] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2008] [Revised: 07/29/2009] [Accepted: 07/29/2009] [Indexed: 10/20/2022]
Abstract
Psoriasis, an inflammatory skin disease, exhibits recurring itching, soreness, and cracked and bleeding skin. Currently, the topical delivery of 5-aminolevulinic acid-photodynamic therapy (ALA-PDT) is an optional treatment for psoriasis which provides long-term therapeutic effects, is non-toxic and enjoys better compliance with patients. However, the precursor of ALA is hydrophilic, and thus its ability to penetrate the skin is limited. Also, little research has provided a platform to investigate the penetration behavior in disordered skin. We employed a highly potent ethosomal carrier (phosphatidylethanolamine; PE) to investigate the penetration behavior of ALA and the recovery of skin in a hyperproliferative murine model. We found that the application of ethosomes produced a significant increase in cumulative amounts of 5-26-fold in normal and hyperproliferative murine skin samples when compared to an ALA aqueous solution; and the ALA aqueous solution appeared less precise in terms of the penetration mode in hyperproliferative murine skin. After the ethosomes had been applied, the protoporphyrin IX (PpIX) intensity increased about 3.64-fold compared with that of the ALA aqueous solution, and the penetration depth reached 30-80 microm. The results demonstrated that the ethosomal carrier significantly improved the delivery of ALA and the formation of PpIX in both normal and hyperproliferative murine skin samples, and the expression level of tumor necrosis factor (TNF)-alpha was reduced after the ALA-ethosomes were applied to treat hyperproliferative murine skin. Furthermore, the results of present study encourage more investigations on the mechanism of the interaction with ethosomes and hyperproliferative murine skin.
Collapse
Affiliation(s)
- Yi-Ping Fang
- School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan
| | | | | | | |
Collapse
|
7
|
van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2009; 182:5836-45. [PMID: 19380832 DOI: 10.4049/jimmunol.0802999] [Citation(s) in RCA: 1488] [Impact Index Per Article: 99.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder. Recently, a crucial role was proposed for the IL-23/IL-17 axis in psoriasis. We hypothesized that IMQ-induced dermatitis in mice can serve as a model for the analysis of pathogenic mechanisms in psoriasis-like dermatitis and assessed its IL-23/IL-17 axis dependency. Daily application of IMQ on mouse back skin induced inflamed scaly skin lesions resembling plaque type psoriasis. These lesions showed increased epidermal proliferation, abnormal differentiation, epidermal accumulation of neutrophils in microabcesses, neoangiogenesis, and infiltrates consisting of CD4(+) T cells, CD11c(+) dendritic cells, and plasmacytoid dendritic cells. IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells. IMQ-induced dermatitis was partially dependent on the presence of T cells, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor, demonstrating a pivotal role of the IL-23/IL-17 axis. In conclusion, the sole application of the innate TLR7/8 ligand IMQ rapidly induces a dermatitis closely resembling human psoriasis, critically dependent on the IL-23/IL-17 axis. This rapid and convenient model allows further elucidation of pathogenic mechanisms and evaluation of new therapies in psoriasis.
Collapse
Affiliation(s)
- Leslie van der Fits
- Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- Michael P Schön
- Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine and Department of Dermatology, University of Würzburg, 97078 Würzburg, Germany.
| |
Collapse
|
9
|
Arakura F, Hida S, Ichikawa E, Yajima C, Nakajima S, Saida T, Taki S. Genetic control directed toward spontaneous IFN-alpha/IFN-beta responses and downstream IFN-gamma expression influences the pathogenesis of a murine psoriasis-like skin disease. THE JOURNAL OF IMMUNOLOGY 2007; 179:3249-57. [PMID: 17709541 DOI: 10.4049/jimmunol.179.5.3249] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Psoriasis is an inflammatory skin disease, onset and severity of which are controlled by multiple genetic factors; aberrant expression of and responses to several cytokines including IFN-alpha/IFN-beta and IFN-gamma are associated with this "type 1" disease. However, it remains unclear whether genetic regulation influences these cytokine-related abnormalities. Mice deficient for IFN regulatory factor-2 (IRF-2) on the C57BL/6 background (IRF-2(-/-)BN mice) exhibited accelerated IFN-alpha/IFN-beta responses leading to a psoriasis-like skin inflammation. In this study, we found that this skin phenotype disappeared in IRF-2(-/-) mice with the BALB/c or BALB/c x C57BL/6 F(1) backgrounds. Genome-wide scan revealed two major quantitative trait loci controlled the skin disease severity. Interestingly, these loci were different from that for the defect in CD4(+) dendritic cells, another IFN-alpha/IFN-beta-dependent phenotype of the mice. Notably, IFN-gamma expression as well as spontaneous IFN-alpha/IFN-beta responses were up-regulated several fold spontaneously in the skin in IRF-2(-/-)BN mice but not in IRF-2(-/-) mice with "resistant" backgrounds. The absence of such IFN-gamma up-regulation in IRF-2(-/-)BN mice lacking the IFN-alpha/IFN-beta receptor or beta(2)-microglobulin indicated that accelerated IFN-alpha/IFN-beta signals augmented IFN-gamma expression by CD8(+) T cells in the skin. IFN-gamma indeed played pathogenic roles as skin inflammation was delayed and was much more infrequent when IRF-2(-/-)BN mice lacked the IFN-gamma receptor. Our current study thus revealed a novel genetic mechanism that kept the skin immune system under control and prevented skin inflammation through regulating the magnitude of IFN-alpha/IFN-beta responses and downstream IFN-gamma production, independently of CD4(+) dendritic cells.
Collapse
Affiliation(s)
- Fuyuko Arakura
- Department of Immunology and Infectious Diseases, Graduate School of Medicine, Shinshu University, 3-1-1 Asahi, Matsumoto 390-8621, Japan
| | | | | | | | | | | | | |
Collapse
|